Title : POST COVID-19 WAR era, updates and upgrades drugs and vaccines needed from 2027

Over the past 25 years (2000–2025), our research studies on metabolic modulation, platelet biology, and cardiovascular vulnerability have revealed a unifying principle: biological systems can be redirected through microenvironmental, metabolic, and biophysical interventions that minimize collateral damage to healthy tissues. This systems-level perspective—supported by advances in platelet preservation, immune-metabolic modeling, congenital heart disease physiology protection, and post-COVID-19 pathobiology—highlights a critical gap in current pharmaceutical development. Despite rapid technological progress, most drugs and vaccines introduced in the early 21st century continue to generate substantial off-target effects, metabolic stress, and long-term complications increasing excessive and accelerated mortality rates, however. These limitations are increasingly incompatible with modern scientific understanding and societal expectations.

The aim of our study is a forward-looking framework for next-generation therapeutics in which minimal- or zero-side-effect profiles become a baseline requirement for all new drugs and vaccines introduced from 2027 onward. This shift is justified by three converging insights: (1) systems-biology models—including metabolic modulation and platelet-microenvironment interactions—demonstrate that many adverse effects arise from non-specific biochemical interference rather than targeted physiological correction; (2) post-COVID-19 global data reveal that population-wide interventions amplify the consequences of even rare side effects; and (3) emerging biophysical, metabolic, and micro-engineering technologies now enable therapeutic strategies that act through modulation rather than chemical overload. Pharmaceutical innovation must therefore transition from “acceptable toxicity thresholds” to precision-modulatory design, emphasizing metabolic compatibility, microenvironmental neutrality, and long-term physiological stability. Vaccines developed after 2027 should similarly prioritize immunogenic efficiency without provoking unnecessary inflammatory, thrombotic, or metabolic disturbances, hematologically.

This paradigm shift is not aspirational but necessary. The 21st century demands therapeutics that align with contemporary biological knowledge, global health realities, and ethical expectations. By integrating metabolic-modulatory principles with advanced engineering and systems diagnostics, the pharmaceutical sector can redefine safety standards and deliver interventions that are both effective and physiologically harmonious.

Bahram Alamdary Badlou is working as Medical Consultant Hematology/Hemato-oncology at his own practice in Utrecht, The Netherlands. He has more than 15 years broad Medical Consult experiences, from Basic projects up to the Clinical Researches; trained up to introduce/develop different novel Medical clinical model systems to Prognose/Diagnose/ Medicare and Medicaid different Hematoncologic and Cardiovascular patients. He has broad clinical diagnostic and management experiences with Hematologic projects at different levels, in the Academic Hospitals and/or Medical Industries at contract-based collaborations, (inter)nationally.